Literature DB >> 24114766

Long-term maintenance of HepaRG cells in serum-free conditions and application in a repeated dose study.

Sebastian Klein1, Daniel Mueller, Valery Schevchenko, Fozia Noor.   

Abstract

Chronic repeated-dose toxicity studies are still carried out on animals and often do not correlate with the effects in human beings mainly due to species-specific differences in biotransformation. The human hepatoma cell line HepaRG has been used for human relevant toxicity assessment. However, HepaRG cells are commonly maintained in serum containing medium which limits their use in 'omics'-based toxicology. In this study, we compared the maintenance of HepaRG cells in standard serum-supplemented and serum-free conditions. Viability and Cytochrome P450 (CYP) activity during long-term cultivation were assessed. Liver-specific albumin and urea production was measured. The extracellular metabolome (amino acids, glucose, lactate and pyruvate) was measured to compare different cultivation conditions using metabolic flux analysis. Although metabolic flux analysis reveals differences in certain parts of the metabolism, e.g. production of urea, the overall metabolism of serum-free and serum-supplemented cultured HepaRG cells is similar. We conclude that HepaRG cells can be maintained in optimized serum-free conditions for 30 days without viability change and with high CYP activity. We also tested the acute (24 h) and long-term repeated-dose (7 doses, every second day) toxicity of valproic acid. We calculated an EC50 value of 1.4 mM after repeated exposure which is close to the cmax value for valproic acid. Maintenance of HepaRG cells in serum-free conditions opens up the opportunity for the use of these cells in human long-term repeated-dose hepatotoxicity studies and for application in systems toxicology.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  HepaRG; Valproic acid; metabolic flux analysis; serum-free; toxicity

Mesh:

Substances:

Year:  2013        PMID: 24114766     DOI: 10.1002/jat.2929

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  10 in total

1.  Evaluation of HepaRG cells for the assessment of indirect drug-induced hepatotoxicity using INH as a model substance.

Authors:  Anika Mann; Thomas Pelz; Knut Rennert; Alexander Mosig; Michael Decker; Amelie Lupp
Journal:  Hum Cell       Date:  2017-05-19       Impact factor: 4.174

2.  Intersection of toxicogenomics and high throughput screening in the Tox21 program: an NIEHS perspective.

Authors:  B Alex Merrick; Richard S Paules; Raymond R Tice
Journal:  Int J Biotechnol       Date:  2015

Review 3.  State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology.

Authors:  Natalie Alépée; Anthony Bahinski; Mardas Daneshian; Bart De Wever; Ellen Fritsche; Alan Goldberg; Jan Hansmann; Thomas Hartung; John Haycock; Helena Hogberg; Lisa Hoelting; Jens M Kelm; Suzanne Kadereit; Emily McVey; Robert Landsiedel; Marcel Leist; Marc Lübberstedt; Fozia Noor; Christian Pellevoisin; Dirk Petersohn; Uwe Pfannenbecker; Kerstin Reisinger; Tzutzuy Ramirez; Barbara Rothen-Rutishauser; Monika Schäfer-Korting; Katrin Zeilinger; Marie-Gabriele Zurich
Journal:  ALTEX       Date:  2014-07-14       Impact factor: 6.043

4.  Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury.

Authors:  Catherine C Bell; Volker M Lauschke; Sabine U Vorrink; Henrik Palmgren; Rodger Duffin; Tommy B Andersson; Magnus Ingelman-Sundberg
Journal:  Drug Metab Dispos       Date:  2017-01-30       Impact factor: 3.922

5.  In-Depth Proteome Analysis Highlights HepaRG Cells as a Versatile Cell System Surrogate for Primary Human Hepatocytes.

Authors:  Georg Tascher; Audrey Burban; Sandrine Camus; Marine Plumel; Stéphanie Chanon; Remy Le Guevel; Valery Shevchenko; Alain Van Dorsselaer; Etienne Lefai; Christiane Guguen-Guillouzo; Fabrice Bertile
Journal:  Cells       Date:  2019-02-21       Impact factor: 6.600

6.  Comparison of gene expression and biotransformation activity of HepaRG cells under static and dynamic culture conditions.

Authors:  Loes P M Duivenvoorde; Jochem Louisse; Nicole E T Pinckaers; Tien Nguyen; Meike van der Zande
Journal:  Sci Rep       Date:  2021-05-14       Impact factor: 4.379

7.  Okadaic acid influences xenobiotic metabolism in HepaRG cells.

Authors:  Leonie T D Wuerger; Helen S Hammer; Ute Hofmann; Felicia Kudiabor; Holger Sieg; Albert Braeuning
Journal:  EXCLI J       Date:  2022-08-01       Impact factor: 4.022

Review 8.  In Vitro Models for Studying Chronic Drug-Induced Liver Injury.

Authors:  M Teresa Donato; Gloria Gallego-Ferrer; Laia Tolosa
Journal:  Int J Mol Sci       Date:  2022-09-28       Impact factor: 6.208

9.  Rutin bioconjugates as potential nutraceutical prodrugs: An in vitro and in ovo toxicological screening.

Authors:  Cristina Adriana Dehelean; Dorina Coricovac; Iulia Pinzaru; Iasmina Marcovici; Ioana Gabriela Macasoi; Alexandra Semenescu; Geza Lazar; Simona Cinta Pinzaru; Isidora Radulov; Ersilia Alexa; Octavian Cretu
Journal:  Front Pharmacol       Date:  2022-09-23       Impact factor: 5.988

10.  Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs.

Authors:  Carlota Oleaga; Catia Bernabini; Alec S T Smith; Balaji Srinivasan; Max Jackson; William McLamb; Vivien Platt; Richard Bridges; Yunqing Cai; Navaneetha Santhanam; Bonnie Berry; Sarah Najjar; Nesar Akanda; Xiufang Guo; Candace Martin; Gail Ekman; Mandy B Esch; Jessica Langer; Gladys Ouedraogo; Jose Cotovio; Lionel Breton; Michael L Shuler; James J Hickman
Journal:  Sci Rep       Date:  2016-02-03       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.